The cost of treating all incarcerated people who have hepatitis C with direct-acting antiviral agents (DAAs) greatly stresses correctional facility budgets. Complex federal laws bar pharmaceutical companies from simply discounting expensive medications to prices that facilities can afford. This article discusses means by which correctional facilities may qualify under federal law as “safety-net providers” to allow sale of DAAs at a price <10% of the average manufacturer price (AMP). No new laws would need to be enacted to implement this strategy. Using fiscal year 2018 pricing data from the Georgia Department of Corrections, we derived an estimate for the AMP and then used this estimate to calculate a nominal price. The United States would save ∼$3 billion if manufacturers sold DAAs at a nominal price to correctional facilities. Use of this strategy would help solve the conundrum of how state and county governments can pay for hepatitis C treatment and would ultimately save money for society.
BeckmanA. L., BilinskiA., BoykoR., CampG. M., WallA. T., LimJ. K.…GonsalvesG. S. (2016). New hepatitis C drugs are very costly and unavailable to many state prisoners. Health Affairs, 35, 1893–1901.
3.
CampbellC. A., CanaryL., SmithN., TeshaleE., RyersonA. B., WardJ. W. (2017). State HCV incidence and policies related to HCV preventive and treatment services for persons who inject drugs—United States, 2015-2016. Morbidity and Mortality Weekly Report, 66, 465–469.
4.
CarsonE. A., SabolW. J. (2016). Aging of the state prison population, 1993–2013 (NCJ 248766). Washington, DC: Bureau of Justice Statistics. Retrieved from https://www.bjs.gov/content/pub/pdf/aspp9313.pdf
5.
Centers for Medicare & Medicaid Services. (2018, March8). Response to FOIA request #101020177029. Washington, DC: MJ Simon.
6.
DennistonM. M., JilesR. B., DrobeniucJ., KlevensR. M., WardJ. W., McQuillanG. M., HolmbergS. D. (2014). Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Annals of Internal Medicine, 160, 293–300.
7.
Estelle v. Gamble, 429 U.S. 97 (1976).
8.
Farmer v. Brennan, 511 U.S. 825, 837, 114S. Ct. 1970, 1979, 128L. Ed. 2d 811, 825 (1994).
9.
HeT., LiK., RobertsM. S., SpauldingA. C., AyerT., GrefenstetteJ. J., ChhatwalJ. (2016). Prevention of hepatitis C by screening and treatment in U.S. prisons. Annals of Internal Medicine, 164, 84–92. doi:10.7326/m15-0617
10.
HillA., KhooS., FortunakJ., SimmonsB., FordN. (2014). Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clinical Infectious Diseases, 58, 928–936.
11.
MartinN. K., VickermanP., GrebelyJ., HellardM., HutchinsonS. J., LimaV. D.…HickmanM. (2013). Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology, 58, 1598–1609.
NguyenJ. T., RichJ. D., BrockmannB. W., VohrF., SpauldingA., MontagueB. T. (2015). A budget impact analysis of newly available hepatitis C therapeutics and the financial burden on a state correctional system. Journal of Urban Health, 92, 635–649.
14.
Public Health, 42 C.F.R. § 447.502 (2010a).
15.
Public Health, 42 C.F.R. § 447.504 (2010b).
16.
The Public Health and Welfare, 42 U.S.C. § 1396r-8 (2008).
17.
RosenthalE. S., GrahamC. S. (2016). Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infectious Agents and Cancer, 11, 24.
18.
SpauldingA. C., AdeeM. G., LawrenceR. T., ChhatwalJ., von OehsenW. (2018). Five questions concerning managing hepatitis C in the justice system: Finding practical solutions for HCV elimination. Infectious Disease Clinics of North America, 32, 323–345. doi:10.1016/j.idc.2018.02.014
19.
SpauldingA. C., AndersonE. J., KhanM. A., Taborda-VidarteC. A., PhillipsJ. A. (2017). HIV and HCV in U.S. prisons and jails: The correctional facility as a bellwether over time for the community’s infections. AIDS Reviews, 19, 134–147.
20.
SpauldingA. C., KimA. Y., HarzkeA. J., SullivanJ. C., LinasB. P., BrewerA.…FergusonW. J. (2012). Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. Topics in Antiviral Medicine, 21, 27–35.
21.
SpauldingA. C., PerezS. D., SealsR. M., HallmanM. A., KavaseryR., WeissP. S. (2011). Diversity of release patterns for jail detainees: Implications for public health interventions. American Journal of Public Health, 101, S347–S352.
22.
Taborda VidarteC. A., AndersonE. J., KhanM. A., PhillipsJ. A., SpauldingA. C. (2017). Where is the US hepatitis C epidemic *now*? Putting the “pen” on the map as elimination efforts hunt for remaining cases. Open Forum Infectious Diseases, 4, S195. doi:10.1093/ofid/ofx163
23.
van de VenN., FortunakJ., SimmonsB., FordN., CookeG. S., KhooS., HillA. (2015). Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology, 61, 1174–1182. doi:10.1002/hep.27641
24.
VaranA. K., MercerD. W., SteinM. S., SpauldingA. C. (2014). Hepatitis C seroprevalence among prison inmates since 2001: Still high but declining. Public Health Reports, 129, 187–195.
